|
WITH the
near implementation of the cheaper medicines law, local
pharmaceutical companies are now gearing up for
expansion projects to make sure they will be able to
meet the expected surge in demand in the market.
Marilou
Buensuceso, president of the Philippine Chamber of
Pharmaceutical Industry, said at least 30 Filipino
drug-makers have secured their Good Manufacturing
Practices (GMP) certification from the Bureau of Food
and Drugs (BFAD), which means they have invested to make
their facilities compliant to established standards.
“It
shows that they are committed to expand. Other companies
are still in the process of securing the BFAD seal,”
Buensuceso told the BusinessMirror.
The GMP
certification, which follows the harmonized Asean
(Association of Southeast Asian Nations) standards, is
proof that a local manufacturer is capable of producing
safe and efficacious drugs just like the innovator
brands.
There
are 57 Filipino-owned drug manufacturers in the country,
including United Laboraties, Pharex, Gx International
and Natrapharm, which are among the fastest-growing
national companies because of their branded generic
medicines.
Buensuceso said there are no actual numbers yet on the
size of the existing investments of Philippine
pharmaceutical firms and how much capital they will be
putting in for further expansion.
A small
pharmaceutical plant, however, costs about P100 million,
she said.
Currently, the Philippine drug market is about P107
billion annually and is poised to grow by 8 percent this
year.
The
share of local firms in this, however, is only about 30
percent.
But when
it comes to the number of medicines sold by units,
Buensuceso said the share of local firms is much higher
because they sell the cheaper varieties.
She said
the competitive landscape in the country, especially
with the government providing the policy support for
cheaper medicines to be accessible to the public, is
changing in favor of the local drug manufacturers and
the consumers.
“The
market will continue expanding because those people who
could not buy the full dosage of medicines because of
the high cost will now afford it,” she said.
The
Intellectual Property Office of the Philippines and
other concerned agencies are now finalizing the
implementing rules and regulations of the cheaper
medicines law and will have it ready for publication by
the end of October.
Joey
Ochave, vice president for business development of
Unilab, said the P1.5-billion facility of its new
generic unit Amherst will be operational by the middle
of next year.
Ochave
said the new plant in Laguna will increase the company’s
capacity for its non-penicillin-based liquid drugs and
vitamins by 50 percent.
Buensuceso said in terms of unit sales, the market is
expected to grow by 10 percent to 12 percent. |